Jeito Capital, a global investment company, led a €75m Series B round in NMD Pharma, a clinical-stage biotech dedicated to developing novel and improved treatments for patients living with neuromuscular diseases, with participation from Novo Holdings, Lundbeckfonden BioCapital, INKEF Capital, and the Roche Venture Fund. “This funding will help NMD Pharma evolve significantly and enable us to become a late-stage clinical company with a pipeline of novel therapeutics in development for patients with neuromuscular diseases. I would like to extend my thanks to my team for their work making NMD Pharma the company it is today and for the support and trust shown by our investors, and in particular to Jeito Capital, for leading this round,” Thomas Holm Pedersen, NMD Pharma CEO.